Literature DB >> 11704447

Severity of airway hyperreactivity associated with laryngeal mask airway removal: correlation with volatile anesthetic choice and depth of anesthesia.

A L Pappas1, R Sukhani, J Lurie, J Pawlowski, K Sawicki, A Corsino.   

Abstract

STUDY
OBJECTIVE: To compare the influence of anesthetic depth and choice of volatile anesthetic drug on the incidence and severity of airway hyperreactivity associated with Laryngeal Mask Airway (LMA) removal.
DESIGN: Randomized observer-blinded study.
SETTING: Ambulatory Surgical Center at a University Medical Center. PATIENTS: 123 ASA physical status I and II children undergoing infraumbilical procedures.
INTERVENTIONS: Patients were randomly assigned to one of four treatment groups: Group 1 = anesthetic induction with halothane, maintenance with isoflurane, nitrous oxide (N(2)O), and oxygen (O(2)), LMA removed when child awakened; Group 2 =anesthetic induction and maintenance as in Group 1, LMA removed while child anesthetized with age adjusted 2 minimum alveolar concentration (MAC) end-tidal concentration of isoflurane; Group 3 = anesthetic induction and maintenance with sevoflurane, N(2)O, and O(2), LMA removed when child awakened; Group 4 = anesthetic induction and maintenance as in Group 3, but LMA removed while child anesthetized with age-adjusted 2 MAC end-tidal concentration of sevoflurane.
MEASUREMENTS AND MAIN RESULTS: Severity of airway hyperreactivity was graded as mild, moderate, or severe. A significant difference was not found amongst the four groups with respect to mild and moderate airway hyperreactivity. Severe airway hyperreactivity leading to a critical event [partial or complete laryngospasm with oxygen saturation (SPO(2)) < 85%] was only encountered in Group 1 patients (incidence 13%). Adverse airway events (SPO(2) < 90%, vomiting and bronchospasm) were also significantly higher in Group 1 (p < 0.05). Isoflurane use was independently associated with significantly higher airway hyperreactivity when compared with sevoflurane (p < 0.05).
CONCLUSIONS: Depth of anesthesia during LMA removal does not appear to affect the incidence or severity of airway hyperreactivity when sevoflurane is the maintenance anesthetic. However, awake LMA removal during isoflurane anesthesia results in a higher incidence of adverse airway events and carries the risk of severe airway hyperreactivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704447     DOI: 10.1016/s0952-8180(01)00318-x

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  6 in total

Review 1.  Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease.

Authors:  Michiaki Yamakage; Sohshi Iwasaki; Akiyoshi Namiki
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

2.  Comparison of isoflurane and sevoflurane in anaesthesia for day care surgeries using classical laryngeal mask airway.

Authors:  Dinesh Kumar Sahu; Vinca Kaul; Reena Parampill
Journal:  Indian J Anaesth       Date:  2011-07

3.  Predicted EC₅₀ and EC₉₅ of Remifentanil for Smooth Removal of a Laryngeal Mask Airway Under Propofol Anesthesia.

Authors:  Ji Young Yoo; Hyun Jeong Kwak; Kyung Cheon Lee; Go Wun Kim; Jong Yeop Kim
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

4.  Effective dose 50 of desflurane for laryngeal mask airway removal in anaesthetized children in cataract surgeries with subtenon block.

Authors:  Sameer Sethi; Babita Ghai; Dipika Bansal; Jagat Ram
Journal:  Saudi J Anaesth       Date:  2015-01

5.  Deep vs. Awake Extubation and LMA Removal in Terms of Airway Complications in Pediatric Patients Undergoing Anesthesia: A Systemic Review and Meta-Analysis.

Authors:  Chang-Hoon Koo; Sun Young Lee; Seung Hyun Chung; Jung-Hee Ryu
Journal:  J Clin Med       Date:  2018-10-14       Impact factor: 4.241

Review 6.  Early versus late removal of the laryngeal mask airway (LMA) for general anaesthesia.

Authors:  Preethy J Mathew; Joseph L Mathew
Journal:  Cochrane Database Syst Rev       Date:  2015-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.